|
Model Number 500DM29 |
Device Problems
Mechanical Jam (2983); Insufficient Information (3190)
|
Patient Problems
Host-Tissue Reaction (1297); Congestive Heart Failure (1783); High Blood Pressure/ Hypertension (1908); Thrombus (2101); No Information (3190)
|
Event Date 02/21/2020 |
Event Type
Injury
|
Manufacturer Narrative
|
Product analysis: no product was returned.Conclusion: without the return of the product, no definitive conclusion can be made regarding the clinical observation.If information is provided in the future, a supplemental report will be issued.
|
|
Event Description
|
Medtronic received information that 1 year and 7 days post implant of this 29mm mitral mechanical valve, it was explanted and replaced with a non-medtronic device.The reason for the replacement was not reported.No additional adverse patient effects were reported.
|
|
Manufacturer Narrative
|
Medtronic received additional information that the patient stopped anticoagulation six months prior to the explant.At explant, severe prosthetic mitral valve thrombosis, severe obstruction (immobile cusp and limited motion of the other cusp), severe pulmonary hypertension and deteriorating left ventricular function (ejection fraction 35%, down from 60%) were reported.No additional adverse patient effects were reported. a1: updated h6: coding updated medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Manufacturer Narrative
|
Product analysis: upon receipt at medtronic's quality laboratory, visual examination revealed damage to the sewing cuff which exposed the stiffening ring, which likely occurred during the explant process.Both leaflets were in the closed position with no evidence of damage such as cracks or surface anomalies.Using an actuator to test leaflet movement, the leaflets exhibited limited mobility, likely due to the thrombotic-appearing host tissue observed on the carbon components and the pannus growth on the outflow orifice.Upon cleaning and drying the valve, the leaflets were fully mobile and the inflow and outflow valve hinge mechanisms appeared intact with no evidence of cracks and/or surface anomalies.A layer of off-white glistening pannus remained attached to a segment of the orifice rim with remnants of thick glistening pannus remaining attached to the sewing ring on the inflow and outflow.A layer of pannus appeared to extend into the orifice area, and an unknown amount of pannus appeared to have been removed during explant.Due to the pannus, the carbon subassembly could not be rotated in the sewing ring.Conclusions: the device history record was reviewed and showed that this product met all manufacturing specifications for product released for distribution.No issues were identified that would have impacted this event.The most likely cause of the leaflet motion problems is due to the reported severe thrombus.The most likely cause of the thrombus was the patient stopping the anticoagulation regimen.H6: coding updated medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Search Alerts/Recalls
|
|
|